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See Article, pages 256–263Hepatitis C virus (HCV) frequently causes chronic
hepatitis C (CHC), which with time may advance to
liver ﬁbrosis, cirrhosis, and hepatocellular carcinoma.
In the natural course of HCV infection, HCV RNA
can be found in serum 1–2 weeks after viral encounter,
while HCV-speciﬁc antibodies (to core, envelope and/
or nonstructural [NS] proteins) are usually not detect-
able until 8–9 weeks [1]. Nevertheless, in clinical prac-
tice, screening for anti-HCV antibodies remains the
ﬁrst step towards identifying HCV-infected individuals,
although a positive ﬁnding must be accompanied by
HCV RNA detection before a diagnosis of active infec-
tion can be made [2]. There are several immunoassays
(EIA) currently available for the screening of anti-
HCV antibodies. These include second-generation
Abbott HCV EIA 2.0 (Abbott Diagnostics, IL, USA),
and third-generation Ortho HCV Version 3.0 ELISA
(Ortho-Clinical Diagnostics, NY, USA) [2]. The
fourth-generation EIA Innotest-HCV-AbIV (Innogenet-
ics, Belgium) is thought to be superior for sensitivity and
speciﬁcity over that of third generation assays [3].
Although all of these tests employ a cocktail of recombi-
nant HCV antigens which may include core, envelope,
and/or NS, they diﬀer with respect to the actual
sequence of the peptides used for antibody capture.0168-8278/$34.00  2008 European Association for the Study of the Liver.
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E-mail address: timich@mun.ca (T.I. Michalak).In the past few years, data from several research
groups have revealed the presence of occult HCV infec-
tion (OCI), as evidenced by small amounts of HCV
RNA in serum and a low-level virus replication in
peripheral blood mononuclear cells (PBMC) and/or
liver, in persons with spontaneous or therapeutically-
induced resolution of hepatitis C [4–9]. Parallel to this
revelation, in a series of studies conducted by Dr. Car-
reno and colleagues [10–12], OCI was also identiﬁed in
individuals who were apparently non-reactive for anti-
HCV antibodies by standard clinical assays but had per-
sistently elevated liver enzyme levels in sera. However,
unlike OCI which continues after termination of symp-
tomatic hepatitis C mentioned above, the etiology of
this form of low-level HCV carriage is unknown. For
clarity, these two potentially distinctive forms of OCI
are referred to here as secondary and crytogenic, respec-
tively. It is necessary to emphasize that their identiﬁca-
tion was possible only after introduction of highly
sensitive nucleic acid ampliﬁcation assays capable of
detecting HCV RNA at levels below the cut-oﬀs of stan-
dard clinical tests, i.e., <2.5 virus genome equivalents
(vge)/reaction.
In this issue of the Journal, Quiroga and colleagues
[13] report ﬁndings of whether patients with cryptogenic
OCI carry antibodies of IgG class directed against an
immunodominant epitope of HCV core protein, and
whether the aforementioned antibodies may be relevant
to the identiﬁcation of this otherwise serologically silent
form of OCI. In a cohort of over 140 patients examined,
40% were found positive for the IgG anti-HCV core
antibody, including 10% of individuals who were anti-
body non-reactive at the time of the ﬁrst sample testing.Published by Elsevier B.V. All rights reserved.
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evaluated antibody against a single N-terminal epitope
(amino acids 5–19) of the core protein. Nevertheless,
one may argue that the data are not entirely unexpected
for a couple of reasons. First, the core polypeptide, with
several conserved epitope clusters, is thought to be the
most immunogenic among the HCV proteins [14], and
is able to elicit a more pronounced humoral response
than the other HCV antigens in acute, chronic or
resolved hepatitis C [15–17]. Second, in patients with
resolved or progressing CHC, the most frequently iden-
tiﬁable antibodies are those directed against epitopes
located towards the N-terminal half of the core protein
[16], the same region Quiroga et al. chose to study.
Despite the apparent success in speciﬁcity, the sensitiv-
ity of the IgG anti-HCV core detection in cryptogenic
OCI was low, as over 60% of the patients remained non-
reactive. On the one hand, it could be that the antibody
levels ﬂuctuate or are present at levels below the detection
limit of the assay, which is not surprising since HCV-spe-
ciﬁc antibodies identiﬁable by current assays can be nar-
rowly focussed, low in titers and delayed in appearance
[15]. Since the HCV core protein contains multiple immu-
nodominant B cell epitopes outside the amino acid 5–19
sequence [16], it is conceivable that seemingly seronega-
tive patients with cryptogenic OCI may have anti-HCV
antibodies which are directed against other epitopes of
the protein. In this regard, detection of seronegative
OCI may be improved through the establishment of an
assay which could simultaneously screen for antibodies
speciﬁc for diﬀerent epitopes of the core protein. On the
other hand, one has to also look at the level of viral anti-
gens available to trigger humoral immunity. HCV repli-
cation in patients with OCI is generally very low. The
diﬃculty of even detecting HCV RNA in serum [12] in
individuals with cryptogenic OCI is suggestive of low, if
any, circulating viral antigens. As such, this level of anti-
genic stimulation may simply be below the threshold
required to induce and/or sustain a detectable humoral
immune response.
In their latest work, Quiroga et al. [13] stated that the
number of HCV-infected hepatocytes detected by in situ
hybridization was seemingly higher in patients who
tested positive for the anti-HCV core antibody than
those who did not. However, unless one could actually
quantify the level of HCV RNA and/or viral protein
in these infected hepatocytes, it would be very diﬃcult
to equate a higher number of infected cells with IgG
anti-HCV core antibody positivity. Along this line,
despite that signs of necroinﬂammation were thought
to be more frequently observed in individuals who were
anti-HCV core antibody reactive, the data available do
not allow for ascribing any direct pathogenic relevance
of the OCI to the persistently elevated liver enzymes
found in these individuals.Although PBMC from patients with cryptogenic OCI
have been shown to be a reservoir for HCV replication
[10,11], it was not established if PBMC, especially B
and T cells, from this patient cohort were infected with
HCV, and if so, whether virus expression in immune
cells in patients tested positive for IgG anti-HCV core
antibody would be diﬀerent from those who did not.
Along this line, it would be of interest to determine
whether HCV infection of lymphoid cells in general,
and B cells in particular, would lead to an alteration
in the ability to make antibody by B cells. In addition
to humoral immunity, exposure to HCV also mounts a
cellular immune response, although its strength varies
depending on a number of host and virus-related fac-
tors. To date, there have been many reports which doc-
umented the presence of HCV-speciﬁc T cell responses
in individuals who had no detectable anti-HCV anti-
body, as determined by standard clinical assays [18–
20]. For example, sexual contacts of patients with acute
hepatitis C were found to exhibit both proliferative and
cytotoxic T cell responses to recombinant HCV antigens
without developing HCV-speciﬁc antibodies [18]. Simi-
larly, T cells from injection drug users who were persis-
tently negative for anti-HCV antibodies could make
high levels of gamma-interferon following ex vivo stim-
ulation with HCV peptides [19]. In an earlier work
[20], Quiroga et al. documented the presence of HCV-
speciﬁc T cell responses, albeit intermittently, in more
than 50% of patients with cryptogenic OCI. Taken
together, the data argue that testing of appropriately tai-
lored HCV-speciﬁc humoral and cellular immune
responses may provide a surrogate marker to the diag-
nosis of past exposure to low-dose HCV leading to pri-
mary OCI, to the conﬁrmation of the existence of
secondary OCI, and to the determination of the kinetics
and potential reactivation of OCI.
In summary, the data by Quiroga et al. [13] oﬀer
novel insights which could potentially pave the way
towards better diagnosis of OCI in patients with abnor-
mally high liver enzymes of currently unknown etiology.
The ﬁnding that a number of patients with cryptogenic
OCI who were initially nonreactive for IgG anti-HCV
core antibodies became positive upon subsequent testing
underscores the necessity of screening serial samples, as
has been recognized in previous works [5,21]. The study
also highlights the need for the development of clinically
applicable assays detecting anti-HCV core antibodies at
a high sensitivity, an eﬀort which is actively pursued by
some laboratories in the industry.References
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